Company registration number 07316438 (England and Wales)
REACT & RECOVER MEDICAL GROUP LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
REACT & RECOVER MEDICAL GROUP LIMITED
COMPANY INFORMATION
Directors
Elizabeth Sarah Comley
Nils Ian Stoesser
Company number
07316438
Registered office
First Floor
Lee House
90 Great Bridgewater Street
Manchester
United Kingdom
M1 5JW
REACT & RECOVER MEDICAL GROUP LIMITED
CONTENTS
Page
Directors' report
1
Statement of comprehensive income
3
Balance sheet
4
Statement of changes in equity
5
Notes to the financial statements
6 - 12
REACT & RECOVER MEDICAL GROUP LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The directors present their annual report and unaudited financial statements for the year ended 31 December 2024.

Principal activities

The Company has been dormant as defined in Section 1169 of the Companies Act 2006 throughout the current financial year. It is anticipated that the Company will remain dormant for the foreseeable future. In the prior year the principal activity was that of a holding company.

Results and dividends

The results for the year are set out on page 3. The Directors do not recommend the payment of a dividend in respect of the current year (2023: £nil)

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Elizabeth Sarah Comley
Nils Ian Stoesser
Going concern

The directors have assessed the balance sheet and likely future cash flows at the date of approving these financial statements. Given the Company is dormant and has no external liabilities, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Exemption From Preparing a Strategic Report

The Company has taken advantage of the exemption in Section 414 A(2) of the Companies Act 2006 from the requirement to prepare a Strategic Report and in preparing the Directors' Report on the basis that it would be entitled to prepare financial statements for the year in accordance with the small companies regime but for being a member of an ineligible group.

 

On behalf of the board
Nils Ian Stoesser
Director
24 September 2025
REACT & RECOVER MEDICAL GROUP LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) including FRS 101 “Reduced Disclosure Framework”. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

 

In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

REACT & RECOVER MEDICAL GROUP LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
2024
2023
Notes
£
£
Turnover
-
-
Administrative expenses
-
0
(70)
Operating profit/(loss)
-
(70)
Tax on profit/(loss)
4
-
0
-
0
Profit/(loss) and total comprehensive income for the financial year
-
0
(70)

All amounts are derived from continuing operations.

 

There were no items of other comprehensive income or losses for the current or prior year other than those included in the Profit and Loss Account, accordingly no Statement of Comprehensive Income is presented.

The notes on pages 6 to 12 form part of these financial statements.

REACT & RECOVER MEDICAL GROUP LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 4 -
2024
2023
Notes
£
£
£
£
Fixed assets
Investments
5
300
300
Current assets
Debtors
7
101,294
101,294
Cash at bank and in hand
1,070
1,070
102,364
102,364
Creditors: amounts falling due within one year
8
(61,443)
(61,443)
Net current assets
40,921
40,921
Net assets
41,221
41,221
Capital and reserves
Called up share capital
9
201
201
Profit and loss reserves
41,020
41,020
Total equity
41,221
41,221

The notes on pages 6 to 12 form part of these financial statements.

React and Recover Medical Group Limited (registered number: 07316438) did not trade during the current financial year and has made neither profit nor loss, nor any other comprehensive income. For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors’ responsibilities:

 

The financial statements were approved by the board of directors and authorised for issue on 24 September 2025 and are signed on its behalf by:
Nils Ian Stoesser
Director
Company registration number 07316438 (England and Wales)
REACT & RECOVER MEDICAL GROUP LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2023
201
41,090
41,291
Year ended 31 December 2023:
Loss and total comprehensive loss
-
(70)
(70)
Balance at 31 December 2023
201
41,020
41,221
Year ended 31 December 2024:
Profit and total comprehensive income
-
-
0
-
0
Balance at 31 December 2024
201
41,020
41,221

The notes on pages 6 to 12 form part of these financial statements.

REACT & RECOVER MEDICAL GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
1
Accounting policies
Company information

React & Recover Medical Group Limited is a private company limited by shares incorporated in England and Wales. The registered office is First Floor, Lee House, 90 Great Bridgewater Street, Manchester, United Kingdom, M1 5JW. The Company's principal activities and nature of its operations are disclosed in the directors' report. The financial statements have been prepared on a going concern basis and is assessed below.

1.1
Accounting convention

The financial statements have been prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework (FRS 101) and in accordance with applicable accounting standards.

The financial statements are prepared in sterling, which is the functional currency of the Company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The Company has taken advantage of the exemption under section 400 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the Company as an individual entity and not about its group.

 

As permitted by FRS 101, the Company has taken advantage of the following disclosure exemptions from the requirements of IFRS:

 

 

Where relevant, equivalent disclosures have been given in the Group accounts of Slater and Gordon UK Holdings Limited and these financial statements may be obtained from First Floor, Lee House, 90 Great Bridgewater Street, Manchester, England, M1 5JW, see note 10.

1.2
Going concern

The directors have assessed the balance sheet and likely future cash flows at the date of approving thesetrue financial statements. Given the Company is dormant and has no external liabilities, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements

1.3
Fixed asset investments

Investments in subsidiaries are stated at cost. Impairment reviews are carried out if there is an indication that the carrying value of the investments may have been impaired. Any impairment loss is charged to the statement of comprehensive income during the reporting period in which the loss is incurred.

1.4
Cash at bank and in hand

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

REACT & RECOVER MEDICAL GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 7 -
1.5
Financial assets

Financial assets are recognised in the Company's balance sheet when the Company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.

 

At initial recognition, financial assets classified as fair value through profit and loss are measured at fair value and any transaction costs are recognised in profit or loss. Financial assets not classified as fair value through profit and loss are initially measured at fair value plus transaction costs.

Financial assets at fair value through profit or loss

When any of the above-mentioned conditions for classification of financial assets is not met, a financial asset is classified as measured at fair value through profit or loss. Financial assets measured at fair value through profit or loss are recognized initially at fair value and any transaction costs are recognised in profit or loss when incurred. A gain or loss on a financial asset measured at fair value through profit or loss is recognised in profit or loss, and is included within finance income or finance costs in the statement of income for the reporting period in which it arises.

Financial assets held at amortised cost

Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (eg trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary.

Financial assets at fair value through other comprehensive income

Debt instruments are classified as financial assets measured at fair value through other comprehensive income where the financial assets are held within the Company’s business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

 

A debt instrument measured at fair value through other comprehensive income is recognised initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognised through other comprehensive income are directly transferred to profit or loss when the debt instrument is derecognised.

The Company has made an irrevocable election to recognize changes in fair value of investments in equity instruments through other comprehensive income, not through profit or loss. A gain or loss from fair value changes will be shown in other comprehensive income and will not be reclassified subsequently to profit or loss. Equity instruments measured at fair value through other comprehensive income are recognized initially at fair value plus transaction cost directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognized through other comprehensive income are directly transferred to retained earnings when the equity instrument is derecognized or its fair value substantially decreased. Dividends are recognized as finance income in profit or loss.

REACT & RECOVER MEDICAL GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 8 -
Impairment of financial assets

Financial assets carried at amortised cost and FVOCI are assessed for indicators of impairment at each reporting end date.

 

The expected credit losses associated with these assets are estimated on a forward-looking basis. A broad range of information is considered when assessing credit risk and measuring expected credit losses, including past events, current conditions, and reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument.

 

For trade receivables, they are held at amortised cost less any impairment provisions and this equates to their recoverable value.

 

Collectability of intercompany and related party balances is reviewed at each reporting period. Management considers whether an impairment is required based upon recoverability. Debts that are known to be uncollectable are written off when identified.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership to another entity.

1.6
Financial liabilities

The Company recognises financial debt when the Company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either 'financial liabilities at fair value through profit or loss' or 'other financial liabilities'.

Other financial liabilities

Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding.

Derecognition of financial liabilities

Financial liabilities are derecognised when, and only when, the Company’s obligations are discharged, cancelled, or they expire.

1.7
Equity instruments

Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

REACT & RECOVER MEDICAL GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 9 -
Deferred tax

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the Company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Critical accounting estimates and judgements

In the application of the Company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

 

The directors do not consider that any critical judgements have been made in the application of the Company's accounting policies and no key sources of estimation uncertainty have been identified that have a significant risk of causing a material misstatement to the carrying amount of assets and liabilities within the financial year.

3
Employees

The Company had no employees in the current or prior year.

Directors' emoluments for both the current year and prior year were settled on behalf of the Company by a Group Company, Slater and Gordon (UK) 1 Limited. The directors do not believe it is practicable to apportion this amount between their services as directors of the Company and their services as directors of fellow Group companies.

REACT & RECOVER MEDICAL GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
4
Taxation
2024
2023
£
£
Current tax
-
0
-
0
Deferred tax
-
0
-
0
Total tax charge
-
0
-
0

The charge for the year can be reconciled to the loss per the profit and loss account as follows:

2024
2023
£
£
Loss before taxation
-
0
(70)
Expected tax credit based on a corporation tax rate of 25.00% (2023: 23.50%)
-
0
(16)
Group relief
-
0
16
Taxation charge for the year
-
-

Factors that may affect future tax charges

 

The Finance Act 2021, which was substantively enacted on 24 May 2021, included an increase to the UK Corporation Tax rate (effective from 1 April 2023) to 25% (for companies with profits over £250,000) and continues to be 19% (for companies with profits of £50,000 or less). Companies with profits between £50,000 and £250,000 pay tax at the main rate reduced by a marginal relief providing a gradual increase in the effective Corporation Tax rate.

5
Investments
Current
Non-current
2024
2023
2024
2023
£
£
£
£
Investments in subsidiaries
-
-
300
300
REACT & RECOVER MEDICAL GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
6
Subsidiaries

Details of the Company's subsidiaries at 31 December 2024 are as follows:

Name of undertaking
Registered office
Principal activities
Class of
% Held
shares held
Direct
React Medical Management Limited
First Floor, Lee House, 90 Great Bridgewater Street, Manchester,                 MI 5JW
Medical reporting
Ordinary
100.00
React Medical Reporting Limited
First Floor, Lee House, 90 Great Bridgewater Street, Manchester,                MI 5JW
Medical reporting
Ordinary
100.00
Recover Healthcare Limited
First Floor, Lee House, 90 Great Bridgewater Street, Manchester,                MI 5JW
Rehabilitation services
Ordinary
100.00
Medicalaw Limited
First Floor, Lee House, 90 Great Bridgewater Street, Manchester,                MI 5JW
Medico-legal services
Ordinary
100.00
7
Debtors
2024
2023
£
£
Amount owed by parent undertaking
54,916
54,916
Amounts owed by related parties
46,378
46,378
101,294
101,294

Amounts owed by parent undertaking and related parties do not attract interest and are repayable on demand.

8
Creditors
2024
2023
£
£
Amounts owed to related parties
61,443
61,443

Amounts owed to related parties do not attract interest and are repayable on demand.

 

9
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
200
200
200
200
B Ordinary shares of £1 each
1
1
1
1
201
201
201
201
REACT & RECOVER MEDICAL GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 12 -
10
Controlling party

The immediate parent company is Slater & Gordon (UK) 1 Limited, a company registered in England and Wales. The ultimate parent undertaking and controlling party is Slater and Gordon UK Holdings Limited, a company incorporated in England and Wales and is both the smallest and largest parent company preparing group financial statements. Copies of the consolidated accounts of Slater and Gordon UK Holdings Limited can be obtained from First Floor, Lee House, 90 Great Bridgewater Street, Manchester, M1 5JW.

2024-12-312024-01-01Elizabeth Sarah ComleyNils Ian StoesserfalsetrueCCH SoftwareiXBRL Review & Tag 2025.22073164382024-01-012024-12-3107316438bus:Director12024-01-012024-12-3107316438bus:Director22024-01-012024-12-3107316438bus:RegisteredOffice2024-01-012024-12-31073164382024-12-31073164382023-01-012023-12-3107316438core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3107316438core:RetainedEarningsAccumulatedLosses2023-01-012023-12-31073164382023-12-3107316438core:ShareCapital2024-12-3107316438core:ShareCapital2023-12-3107316438core:RetainedEarningsAccumulatedLosses2024-12-3107316438core:RetainedEarningsAccumulatedLosses2023-12-31073164382022-12-3107316438core:ShareCapitalOrdinaryShares2024-12-3107316438core:ShareCapitalOrdinaryShares2023-12-3107316438core:Subsidiary12024-01-012024-12-3107316438core:Subsidiary22024-01-012024-12-3107316438core:Subsidiary32024-01-012024-12-3107316438core:Subsidiary42024-01-012024-12-3107316438core:Subsidiary112024-01-012024-12-3107316438core:Subsidiary222024-01-012024-12-3107316438core:Subsidiary332024-01-012024-12-3107316438core:Subsidiary442024-01-012024-12-3107316438core:CurrentFinancialInstruments2024-12-3107316438core:CurrentFinancialInstruments2023-12-3107316438bus:PrivateLimitedCompanyLtd2024-01-012024-12-3107316438bus:FRS1012024-01-012024-12-3107316438bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3107316438bus:EntityNoLongerTradingButTradedInPast2024-01-012024-12-3107316438bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP